DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Brain Cancer Market Forecast
Some of the key facts of the Brain Cancer Market Report:
- The Brain Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to a Cancer.Net article from 2020, brain tumours make up 85–90% of all primary CNS tumours. The report also stated that primary malignant tumours of the brain and spinal cord were anticipated to be detected in 23,890 adults (13,590 men and 10,300 women) in the United States in 2020
- About 70–80% of initial brain tumours are High-Grade Gliomas, according to Brain Tumour UK. Men are affected more frequently than women between the ages of 46 and 50, when they most frequently occur
- In the seven biggest markets, there were 60,630 Primary Brain Tumour incidents overall in 2021
- During the projected period of 2021-2032, the incident population of Primary Brain Tumours in the 7 MM is anticipated to grow at a CAGR of 0.88%
- Key Brain Cancer Companies: Orbus Therapeutics, Kazia Therapeutics, Bayer, AstraZeneca, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Istari Oncology, Servier, Bristol-Myers Squibb, Eisai Inc., Celtic Pharma, Guerbet, Shanghai Henlius Biotech, Eli Lilly and Company, Crown Bioscience, Bracco Diagnostics, Inc, Bayer, Pfizer, and others
- Key Brain Cancer Therapies: Eflornithine + Lomustine, Paxalisib, Regorafenib, Durvalumab, ITI-1000, VAL-083, MDNA55, Lerapolturev, Vorasidenib, Nivolumab, GLIADEL, Temozolomide, hCRF, Dotarem®, HLX208, abemaciclib, Karenitecin (BNP1350), Multihance, Magnevist (SH L 451A), dalteparin, and others
- The Brain Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Brain Cancer pipeline products will significantly revolutionize the Brain Cancer market dynamics.
Brain Cancer Overview
An intracranial tumour, also referred to as a brain tumour, is one of several disorders that share the abnormal growth of mass lesions in the brain, spinal cord, or its coverings. There are two basic categories of brain tumours: primary and metastatic.
Get a Free sample for the Brain Cancer Market Report
https://www.delveinsight.com/report-store/brain-cancer-market
Brain Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Brain Cancer Epidemiology Segmentation:
The Brain Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Brain Cancer
- Prevalent Cases of Brain Cancer by severity
- Gender-specific Prevalence of Brain Cancer
- Diagnosed Cases of Episodic and Chronic Brain Cancer
Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Epidemiology Forecast
Brain Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Brain Cancer market or expected to get launched during the study period. The analysis covers Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Brain Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Brain Cancer Therapies and Key Companies
- Eflornithine + Lomustine: Orbus Therapeutics
- Paxalisib: Kazia Therapeutics
- Regorafenib: Bayer
- Durvalumab: AstraZeneca
- ITI-1000: Immunomic Therapeutics
- VAL-083: Kintara Therapeutics
- MDNA55: Medicenna Therapeutics
- Lerapolturev: Istari Oncology
- Vorasidenib: Servier
- Nivolumab: Bristol-Myers Squibb
- GLIADEL: Eisai Inc.
- Temozolomide: Bristol-Myers Squibb
- hCRF: Celtic Pharma
- Dotarem®: Guerbet
- HLX208: Shanghai Henlius Biotech
- abemaciclib: Eli Lilly and Company
- Karenitecin (BNP1350): Crown Bioscience
- Multihance: Bracco Diagnostics, Inc
- Magnevist (SH L 451A): Bayer
- dalteparin: Pfizer
Discover more about therapies set to grab major Brain Cancer market share @ Brain Cancer Treatment Market
Brain Cancer Market Drivers
- Robust Pipeline Activity
- Increase in Reimbursement and Insurance Policies
- Interventions that can Cross the Blood–Brain Barrier
- Development of Intratumoral therapies
- Upcoming Launches and Approval
- Increasing Awareness Programs
Brain Cancer Market Barriers
- Use of Off-label Therapies and Generics
- Fewer Patients Available for Clinical Trials for current therapies
- High Recurrence Rate
- Multiple Treatment Challenges
- High-treatment Costs
Scope of the Brain Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Brain Cancer Companies: Orbus Therapeutics, Kazia Therapeutics, Bayer, AstraZeneca, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Istari Oncology, Servier, Bristol-Myers Squibb, Eisai Inc., Bristol-Myers Squibb, Celtic Pharma, Guerbet, Shanghai Henlius Biotech, Eli Lilly and Company, Crown Bioscience, Bracco Diagnostics, Inc, Bayer, Pfizer, and others
- Key Brain Cancer Therapies: Eflornithine + Lomustine, Paxalisib, Regorafenib, Durvalumab, ITI-1000, VAL-083, MDNA55, Lerapolturev, Vorasidenib, Nivolumab, GLIADEL, Temozolomide, hCRF, Dotarem®, HLX208, abemaciclib, Karenitecin (BNP1350), Multihance, Magnevist (SH L 451A), dalteparin, and others
- Brain Cancer Therapeutic Assessment: Brain Cancer current marketed and Brain Cancer emerging therapies
- Brain Cancer Market Dynamics: Brain Cancer market drivers and Brain Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Brain Cancer Unmet Needs, KOL’s views, Analyst’s views, Brain Cancer Market Access and Reimbursement
To know more about Brain Cancer companies working in the treatment market, visit @ Brain Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Brain Cancer Market Report Introduction
2. Executive Summary for Brain Cancer
3. SWOT analysis of Brain Cancer
4. Brain Cancer Patient Share (%) Overview at a Glance
5. Brain Cancer Market Overview at a Glance
6. Brain Cancer Disease Background and Overview
7. Brain Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Brain Cancer
9. Brain Cancer Current Treatment and Medical Practices
10. Brain Cancer Unmet Needs
11. Brain Cancer Emerging Therapies
12. Brain Cancer Market Outlook
13. Country-Wise Brain Cancer Market Analysis (2019–2032)
14. Brain Cancer Market Access and Reimbursement of Therapies
15. Brain Cancer Market Drivers
16. Brain Cancer Market Barriers
17. Brain Cancer Appendix
18. Brain Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services